Intermittent Intravenous Levosimendan in Ambulatory Advanced Chronic Heart Failure Patients

Summary

The purpose of this study is to determine the safety and efficacy of intravenous administration of intermittent doses of levosimendan (infusions of 0,2 μg/kg/min, of levosimendan or placebo, without bolus, for 6 hours every 2 weeks) compared to placebo in ambulatory patients with advanced chronic heart failure.

Timeline

Start

2010-04

Primary completion

2013-10

Completion

2015-11

Drugs

Indications